China Hemofiltration Machine Market Size & Outlook, 2025-2033
China Hemofiltration Machine Market Insights
- As highlighted in Reed Intelligence analysis, the China Hemofiltration Machine Market, worth USD 102.89 Million in 2024, is forecasted to achieve USD 159.92 Million by 2033.
- The China market is anticipated to grow at a CAGR of 5.02% during the period 2026–2033.
- By 2024, Acute Kidney Injury represented the largest share of the Application market size.
- Therapeutic Apheresis is expected to remain the key growth driver within Application, registering the fastest CAGR during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, China held 5.88% of the global Hemofiltration Machine Market size.
- By 2033, United States is anticipated to capture the largest share of the global Hemofiltration Machine Market.
- In Asia Pacific, China is expected to lead the regional Hemofiltration Machine Market size by 2033.
- Singapore will remain the fastest-growing market in Asia Pacific, reaching USD 10.34 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 102.89 Million |
| Market Size In 2033 | USD 159.92 Million |
| Largest segment | Acute Kidney Injury |
| Units | Revenue in USD Million |
| CAGR | 5.02% (2025-2033) |
| Segmnetation Covered | |
| Application |
|
| End Use |
|
| Product Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
China Hemofiltration Machine Market Application 2025-2033 (USD Million)
| Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute Kidney Injury | XX.x | XX.x | XX.x | 53.78 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Chronic Kidney Disease | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Therapeutic Apheresis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
China Hemofiltration Machine Market End Use 2025-2033 (USD Million)
| End Use | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 54.74 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dialysis Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Home Care | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
China Hemofiltration Machine Market Product Type 2025-2033 (USD Million)
| Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Continuous Renal Replacement Therapy Machines | XX.x | XX.x | XX.x | 46.37 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Portable Hemofiltration Machines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Single-Needle Dialysis Machines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
